Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lawsuit: Sandoz Copycat Piggybacks Enbrel, Ducks Duties

This article was originally published in Scrip

Executive Summary

For the second time, Novartis AG unit Sandoz Inc. is trying to "reap the commercial benefits" provided to biosimilar manufacturers under the Biologics Price Competition and Innovation Act (BPCIA), while seeking to avoid the obligations Congress established under the 2010 law "to protect innovators," Amgen Inc. and Roche AG charged in new court documents.

Advertisement

Related Content

Novartis/Sandoz Biosimilar Erelzi OK'd; Covets Enbrel's US Sales
Innovators Employ Labyrinthine Defenses To Fend Off Biosimilars
Enbrel Biosimilar Market In Sandoz's Grasp; Will Cost, Litigation Derail It?

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

SC064635

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel